Preliminary safety of bevacizumab with first-line Folfox, Capox, Folfiri and capecitabine for mCRC-First B.E.A.Trial.

@article{Berry2006PreliminarySO,
  title={Preliminary safety of bevacizumab with first-line Folfox, Capox, Folfiri and capecitabine for mCRC-First B.E.A.Trial.},
  author={S. R. Berry and D. Hamish Cunningham and Michael Michael and M Dibartolomeo and F Rivera and Albrecht Kretzschmar and M Mazier and Beatrix Lutiger and E Vancutsem},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2006},
  volume={24 18_suppl},
  pages={3534}
}
3534 Background: In a phase III pivotal trial in patients (pts) with metastatic colorectal cancer (mCRC), bevacizumab (BEV) increased overall survival by 30% when added to first-line IFL chemotherapy (CT). Safety data from controlled BEV trials have been described, and indicate that certain serious adverse events (SAE), primarily gastrointestinal (GI) perforations and arterial thromboembolic events (TE) occurred more often in pts who received CT with BEV than those who received CT alone. First… CONTINUE READING